Gatekeeping Sample Clauses
Gatekeeping. 5.1 The Parties acknowledge that, as of the Commencement Date, the Target has passed CAT’s Gatekeeping Procedure under the Amendment Agreement.
Gatekeeping. A. General Requirements
1) Pursuant to IC 12-26-6-8(c)(1) and IC 12-26-7-3(b)(1), a CMHC shall conduct a face- to-face evaluation of the individuals who are proposed to be committed to a state institution administered by the DMHA and report the findings of the evaluation to the court in which the matter is pending.
2) Pursuant to IC 12-24-12-9 and IC ▇▇-▇▇-▇▇-▇▇(a)(1), a CMHC shall administer within the limits of its service capacity, a continuum of care as required by IC 12-24-19-4 for each individual who meets the following requirements:
a) Has been involuntarily committed under IC 12-26;
b) Is not developmentally disabled; and
c) Has been discharged from a state operated facility or is placed on outpatient status by a state operated facility under IC 12-26.
B. State Operated Facility Bed Allocation for the SMI Population 1) IC 12-21-2-3 allows the director of the DMHA to establish, maintain and reallocate long term care settings and state operated long term care inpatient beds to provide services for patients with long term psychiatric disorders.
Gatekeeping. Zymeworks will designate its Head of Business Development to be the gatekeeper for Target Pairs and he or she, together with appropriate technical employees to assist in Sequence alignment against Zymeworks’ sequence library, will together be the gatekeeper for any Sequence Pairs. Zymeworks will notify BeiGene of the gatekeeper(s) and their contact information promptly following the Effective Date, and any changes thereto promptly following any such change, in writing. BeiGene may designate any Target Pair as a BeiGene Target Pair or replacement BeiGene Target Pair or any Sequence 28 Competitive Information – Commercially Sensitive Terms. 29 Competitive Information – Commercially Sensitive Terms. Pair Directed To a BeiGene Target Pair as a BeiGene Sequence Pair or replacement BeiGene Sequence Pair in accordance with Sections 3.5 through this Section 3.6, as applicable; provided that Zymeworks is not, as of the date that the applicable Zymeworks’ gatekeeper receives BeiGene’s Designation Notice for such Sequence Pair or Target Pair, as applicable:
(a) contractually obligated to grant, in each case pursuant to a written agreement with a Third Party to a Third Party rights with respect to products incorporating such Sequence Pair or Directed To such Target Pair, as applicable;
(b) actively and in good faith engaged in negotiations with a Third Party regarding the development or commercialization of products incorporating such Sequence Pair or Directed To such Target Pair, as applicable […***…];30 or
(c) actively performing or has performed […***…] activities on its own behalf with respect to one or more products incorporating such Sequence Pair or Directed To such Target Pair, pursuant to an […***…].31
Gatekeeping. No later than [**] following Syros’ completion of the analyses under Section 2.8.3(a), Syros shall submit the Supplemental Target List to the Gatekeeper in writing and shall notify Incyte in writing that such list has been submitted to the Gatekeeper. Within [**] after receipt of the Supplemental Target List, the Gatekeeper shall be required to (i) update the Original Target List to add any Supplemental Targets that are not Syros Excluded Targets and (ii) deliver to both Parties in writing the updated Original Target List. Upon the Gatekeeper updating the Original Target List in accordance with this Section 2.8.3(b), each Supplemental Target that is not a Syros Excluded Target shall be deemed to be an Original Target.
Gatekeeping. The Parties acknowledge that, as of the Commencement Date, the Target has passed MedImmune’s Gatekeeping Procedure under the Amended Agreement.
Gatekeeping. If applicable, Syros shall notify the Gatekeeper in writing whether it accepts the Nexus (such acceptance not to be unreasonably withheld). Within [**] after the later of (i) delivery of Incyte’s written notice to the Gatekeeper under Section 3.4.2(b) and (ii) Syros’ written acceptance to the Gatekeeper under the preceding sentence, if applicable, the Gatekeeper shall be required to notify (A) Incyte in writing if any Original Target selected by Incyte for substitution is an Incyte Excluded Target, and the identity of such Incyte Excluded Target; (2) Syros in writing if any Original Target selected by Incyte for substitution is an Incyte Excluded Target, but not the identity of such Incyte Excluded Target; and (3) the Parties in writing if any Original Target selected by Incyte for substitution is (I) a Syros Excluded Target or (II) neither an Incyte Excluded Target nor a Syros Excluded Target. If such Original Target is a Syros Excluded Target or Incyte Excluded Target, then such Original Target shall not be substituted for the applicable Initial Research Target, Definitive Research Target or Extended Research Target. If such Original Target is not a Syros Excluded Target or Incyte Excluded Target, then (x) such Original Target shall be deemed to be substituted for the applicable Initial Research Target, Definitive Research Target or Extended Research Target and (y) the Initial Research Target, Definitive Research Target or Extended Research Target for which such Original Target is substituted shall no longer constitute an Initial Research Target, Definitive Research Target or Extended Research Target, as applicable, and shall become an Unreserved Target, in each case ((x) and (y)), as of the date of the Gatekeeper’s written notice.
Gatekeeping. ▇▇▇ may select any Identified Sequence Pair as a [...***...] or second Collaboration Sequence Pair in accordance with Section 3.5 or Section 3.7, respectively; provided that, as of the date Zymeworks receives the Designation Notice for such Identified Sequence Pair from ▇▇▇: 40
3.6.1 Zymeworks is not contractually obligated to grant, or has not granted, to a Third Party rights with respect to products incorporating such Identified Sequence Pair;
3.6.2 Zymeworks is not actively and in good faith engaged in negotiations with a Third Party regarding the development or commercialization of products incorporating such Identified Sequence Pair [...***...]; 41 and
3.6.3 An Acquiring Entity, directly or through its affiliate (other than Zymeworks), is not actively performing or has not performed activities regarding the development or commercialization of products incorporating such Identified Sequence Pair, which activities were commenced prior to the acquisition of Zymeworks’ assets by such Acquiring Party and are conducted outside of the Research Program.
Gatekeeping. A Sequence and its corresponding Antibody will “Available” if Twist [***].
Gatekeeping. No later than [**] following Syros’ completion of the analyses under Section 2.8.1(a), Syros shall submit the Pilot Target List to the Gatekeeper in writing. Following receipt of the Pilot Target List, the Gatekeeper shall be required to (i) prepare a list of Targets consisting of the Pilot Targets but excluding any Pilot Targets included on the Syros Excluded Target List (such list of Targets prepared by the Gatekeeper, the “Original Target List” and each Target included on the Original Target List an “Original Target”) and (ii) deliver to both Parties in writing the Original Target List.
Gatekeeping